Topic
What GLP-1 drugs are coming next?
Sourced updates on Retatrutide, CagriSema, MariTide and every GLP-1 drug still in development.
CagriSema: FDA Status, Weight Loss Results, and What Comes NextCagriSema is not FDA-approved yet. Novo Nordisk filed on December 18, 2025; the company expects FDA review in 2026, and trade press anticipates a decision by late 2026. In REDEFINE 1, weight loss was 22.7% if all stayed on treatment, 20.4% regardless of adherence.Eli Lilly vs Novo Nordisk: Who's Winning the Weight-Loss Drug Race?Eli Lilly leads the US GLP-1 market with about 57% of prescriptions to Novo Nordisk's 37%, but Novo's Wegovy pill leads the pill race with about 183K weekly prescriptions to Foundayo's 47.5K, per IQVIA estimates cited by analysts. Starting prices have fallen from about $1,000 to $149–$299 per month.How to Join a GLP-1 Clinical Trial in the US: Step by StepTo join a GLP-1 clinical trial, search ClinicalTrials.gov by condition and location, check the eligibility criteria on each study record, and contact the study site directly. Every registered study has an NCT number you can verify, and free services like ResearchMatch (121,864 volunteers) can match you to studies.MariTide: What to Know About the Monthly Weight-Loss InjectionMariTide (maridebart cafraglutide) is Amgen's investigational obesity drug, designed to start with monthly injections and possibly need as few as 4 or 6 doses a year for maintenance. It is in Phase 3 trials, not FDA approved, and the pivotal MARITIME-1 data point is estimated for 2027-01-21.Mazdutide: Weight-Loss Results, Approval Status, and US AvailabilityMazdutide is a dual glucagon/GLP-1 drug approved in China for weight management and type 2 diabetes, not by the FDA. In the Phase 3 GLORY-2 study, the 9 mg dose produced 18.55% mean weight loss over 60 weeks versus 3.02% for placebo.New Weight Loss Drugs Coming Out in 2026: What You Can Actually GetIn 2026, two new weight loss pills are FDA-approved in the US — the Wegovy pill and Foundayo — while CagriSema sits under FDA review and retatrutide, which produced 28.3% average weight loss in trials, is not slated for FDA submission until Q1 2027.New Weight Loss Drugs Coming Out: Ranked by FDA Approval StatusCagriSema is the only new weight-loss drug actually under FDA review, filed December 18, 2025, with review expected in 2026. Retatrutide is next, with a filing planned for Q1 2027, and survodutide has Phase 3 data but no US filing yet.Orforglipron (Foundayo): How the GLP-1 Pill Works, Costs, and ComparesOrforglipron, sold as Foundayo, is Eli Lilly's once-daily GLP-1 weight-loss pill approved by the FDA on April 1, 2026. In its main trial, people on the highest dose lost 12.4% of body weight (27.3 lbs); self-pay runs about $149–$349 per month.Retatrutide: Trial Results, Side Effects, and When You Could Get ItRetatrutide is Eli Lilly's investigational once-weekly triple-agonist injection that produced up to 28.3% (70.3 lbs) average weight loss at 80 weeks in Phase 3. It is not FDA approved, cannot be prescribed, and Lilly plans to file for U.S. approval in Q1 2027.Retatrutide: Weight Loss Results, Side Effects, and When It Could Be ApprovedRetatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1, glucagon). In the Phase 3 TRIUMPH-1 trial, the 12 mg dose produced 28.3% (70.3 lbs) average weight loss at 80 weeks. Lilly plans to file for FDA approval in Q1 2027.Survodutide: Weight Loss Results, Side Effects, and Approval StatusSurvodutide is an investigational once-weekly glucagon/GLP-1 injection from Boehringer Ingelheim. In the Phase 3 SYNCHRONIZE-1 trial it produced up to 16.6% weight loss versus 3.2% for placebo, but it is not FDA-approved and cannot be prescribed yet.VK2735: What to Know About Viking's Weight Loss DrugVK2735 is an investigational GLP-1/GIP drug from Viking Therapeutics, not FDA approved. In Phase 2, the injection cut body weight up to 14.7% and the pill up to 12.2% after 13 weeks; Phase 3 dosing runs into 2027 at the earliest by inference, and Viking has given no approval timeline.When Will Generic Ozempic Be Available in the US?No FDA-approved generic Ozempic exists as of August 2026, and experts do not expect one in the US until at least the end of 2031. India and Canada already have approved generics; the advocacy group I-MAK projects US patents could block entry as far out as 2042.Zenagamtide (Formerly Amycretin): Results, Trials, and AvailabilityZenagamtide is Novo Nordisk's new name for amycretin, an investigational GLP-1/amylin drug not yet approved in the US. In a Phase 2 diabetes study, people lost up to 14.5% of body weight at Week 36 on the injection.